Birdwatch Archive

Birdwatch Note Rating

2023-07-08 22:20:20 UTC - HELPFUL

Rated by Participant: 8524072EFCF1D846CDE79BC27BF6A527CD4E569CEF04D62440ABFD7356D14AE5
Participant Details

Original Note:

The Phase 3 LUCIDITY trial for hydromethylthionine mesylate (HMTM) failed to meet its endpoint as reported on Medscape. Additional trials are underway. The LUCIDITY trial did have encouraging results that TauRx Pharmaceuticals are promoting through PR releases. https://www.prnewswire.com/in/news-releases/lucidity-phase-3-topline-data-presented-at-ctad-for-hmtm--the-only-oral-anti-tau-therapy-in-late-stage-development-301690475.html https://www.medscape.com/viewarticle/984863 https://archive.is/awWDp

All Note Details

Original Tweet

All Information

  • noteId - 1677803233077522432
  • participantId -
  • raterParticipantId - 8524072EFCF1D846CDE79BC27BF6A527CD4E569CEF04D62440ABFD7356D14AE5
  • createdAtMillis - 1688854820743
  • version - 2
  • agree - 0
  • disagree - 0
  • helpful - 0
  • notHelpful - 0
  • helpfulnessLevel - HELPFUL
  • helpfulOther - 0
  • helpfulInformative - 0
  • helpfulClear - 0
  • helpfulEmpathetic - 0
  • helpfulGoodSources - 1
  • helpfulUniqueContext - 0
  • helpfulAddressesClaim - 0
  • helpfulImportantContext - 1
  • helpfulUnbiasedLanguage - 0
  • notHelpfulOther - 0
  • notHelpfulIncorrect - 0
  • notHelpfulSourcesMissingOrUnreliable - 0
  • notHelpfulOpinionSpeculationOrBias - 0
  • notHelpfulMissingKeyPoints - 0
  • notHelpfulOutdated - 0
  • notHelpfulHardToUnderstand - 0
  • notHelpfulArgumentativeOrBiased - 0
  • notHelpfulOffTopic - 0
  • notHelpfulSpamHarassmentOrAbuse - 0
  • notHelpfulIrrelevantSources - 0
  • notHelpfulOpinionSpeculation - 0
  • notHelpfulNoteNotNeeded - 0
  • ratingsId - 16778032330775224328524072EFCF1D846CDE79BC27BF6A527CD4E569CEF04D62440ABFD7356D14AE5